JCJohn Edmund Armourer Common

John Edmund Armourer Common

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


John Edmund Armourer Common has a total of 644 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Towards personalized therapeutics for epidermal differentiation disorders: integrating host genetics, immune-endotypes and the skin microbiome

    by Thomas Sharkey, Mark Eisner, John Common, Neil Rajan

    Epidermal differentiation disorders (EDDs) are a rare, heterogeneous grouping of monogenic disorders. EDDs, comprising the previously termed congenital ichthyosis, are characterized by epidermal barrier dysfunction, cutaneous inflammation and associated morbidity. Immunomodulatory therapies, particularly repurposed biologics, are an emerging approach for management. However, clinical implementation has been impeded by a variable and unpredictable response rate, reflecting the genetic and immunological heterogeneity of EDDs, as well as raising questions over other contributory pathogenic mechanisms. Patient genotyping and immune profiling have revealed a shared immune polarization across EDD subtypes, predominantly T helper (Th)17, with some subtypes demonstrating a mixed immuno-endotype with contribution from Th2 or interleukin (IL)-36 mediated signalling. This improved immunological understanding has informed the repurposing of established biologics targeting IL-4R, IL-17 and IL-12/23, alongside emerging interest in Janus kinase inhibitors. Metagenomic microbiome profiling has revealed a homeostatic disruption across EDD subtypes with depleted commensal organisms, including Cutibacterium acnes and Malassezia species, and enrichment of pathobiont Staphylococcus and Corynebacterium species. Patients may be further stratified into dysbiotic groupings, with pathogenic variant and phenotypic severity influencing microbial composition. Ecological dysbiosis may contribute to immune polarization through an ‘outside–inside–outside’ model of host–microbe interactions, potentially underlying the variable response rates to repurposed biologics. In this review, we propose a ‘host genome and microbiome’ framework for personalized EDD clinical management, integrating the EDD genotype and immuno-endotype (‘host genome’), and cutaneous microbiome as candidate simultaneous stratifiable elements. Genomic diagnosis, spurred by recent EDD reclassification, provides mechanistic context. Immuno-endotyping may enable a rational biologic selection but requires prospective validation. Microbiome profiling may guide emerging therapeutics or serve as a biomarker. We propose that a route to therapeutic restoration in EDD may require simultaneous targeting of the host–microbe axis. Delineation of the complex interplay between host genetics, immuno-endotypes, epidermal barrier dysfunction and skin microbiome is a key priority for future research to bring this approach to the clinic.

  • Open Access

    Host recovery after skin barrier disruption is individual-specific and associated with microbial functions

    by Aarthi Ravikrishnan, Stephen Wearne, Xiuting Li, Ghayathri Balasundaram, Ahmad Nazri Mohamed Naim, Indrik Wijaya, Miao Qin Tay, Alicia Ann May Yap, Poongkulali Rajarahm, Tutie Nooradilah Binte Alui, et al.

    The human skin is repeatedly exposed to mechanical and environmental stress, particularly in common skin diseases such as eczema, and yet the determinants of recovery remain poorly understood. Using longitudinal, multimodal profiling of skin physiology, structure (Raman spectroscopy), and microbial communities (shotgun metagenomics), we investigated in a human cohort (n=36 subjects, ×2 sites, ×6 timepoints) how host-microbe interactions could jointly shape recovery. Despite baseline variability in physiological parameters, we established that our protocol enables a defined disruption of the stratum corneum. While recovery trajectories for host attributes were notably consistent across age groups and body sites, individual-specific differences in recovery timelines were observed. To assess the role of the skin microbiome, several key time-dependent changes in microbial species were identified including enrichment of select Cutibacterium and Staphylococcus species and depletion of Corynebacterium and Malassezia species. Clustering of microbiome stability profiles across subjects and sites identified 6 distinct groups which associate with varying host-recovery patterns and microbial functions. Finally, joint hazards modelling of recovery timing revealed significant contributions from microbial taxa, functions and stability groups, highlighting the under-appreciated role of host-microbial interactions in response to skin stress and in the recovery process.

  • Open Access

    Aspartyl protease MfSAP2 is a key virulence factor in mycelial form of skin fungi Malassezia furfur

    by Wisely Chua, Yuanyuan Hei, Li Fang Koh, Belle Lin Hwee Yap, Hui Ling Saw, Thaís Helena Maciel Fernandes, Elany Barbosa da Silva, Shirlyn Goh, Thomas L. Dawson, Anthony J. O’dOnoghue, et al.

    Malassezia is the dominant genus of fungi residing on human skin and is associated with both healthy skin and many dermatological conditions. Among these skin diseases, pityriasis versicolor (PV) has strong etiological connections with Malassezia. In the hyper- or hypo-pigmented scales of PV patients, Malassezia is enriched in its mycelial form, which is rarely present on healthy skin. How these Malassezia hyphae contribute to disease pathology in PV is unknown. In this study, we observed a distinct shift in the extracellular proteolytic activity when Malassezia furfur transitions from yeast to hyphae. We identified that the expression of the aspartyl protease MfSAP2 is dramatically up-regulated at both the mRNA and protein level when M. furfur is in the mycelial form. We determined the protease substrate specificity and observed that MfSAP2 can degrade corneodesmosome proteins, which are intercellular adhesive proteins between corneocytes in the stratum corneum. In a 3D human skin model with MfSAP2 treatment, we observed clear degradation of corneodesmosin, a component of the corneodesmosome. Taken together, our study demonstrates that a secreted protease is a key virulence factor associated with M. furfur mycelium and is potentially involved in the disease pathogenesis of PV.


  • Open Access

    IFNγ priming enables NLRP3 inflammasome activation in human keratinocytes in vitro

    by Pritisha Rozario, Ying Shiang Lim, Suet Lee Shirley Ding, Muhammad Jasrie Firdaus, Stephen Wearne, Brandon Han Siang Wong, Rae Chua, Kim Samirah Robinson, Tung Sem Julie Chu, Meng Liu, et al.


  • Microbial Makeover: Skin microbiome reset after stem cell transplantation

    by John E. Common, Rebecca P. Payne

  • Ruxolitinib Alleviates Inflammation and Fortifies Skin Barrier Function Through Dampening IL‐13

    by Li Fang Koh, Muhammad Jasrie Firdaus, Yohei Natsuaki, Sho Hanakawa, Khek‐Chian Tham, Declan P. Lunny, Belle L. H. Yap, Satoshi Nakamizo, Eori Nam, Ji Eun Lee, et al.

    Atopic dermatitis (AD) is a prevalent inflammatory skin disorder characterized by an impaired skin barrier, dysregulated immune system and pruritis. Emerging pharmaceutical therapies for AD include selective Janus kinase (JAK) inhibitors such as ruxolitinib, the first dual JAK1/JAK2 inhibitor approved by the US Food and Drug Administration. This study aimed to evaluate the effects of ruxolitinib on AD‐related symptoms using mouse and human skin models. AD‐related symptoms were assessed in MC903/ruxolitinib‐treated mice, including ear swelling, histological analysis, pruritus, serum biomarker quantification and immune cell analysis. Additionally, immunohistochemistry and transcriptome analysis were conducted on AD‐related cytokine‐treated reconstructed human skin (RHS) and ruxolitinib‐treated human skin explants with and without tape‐stripping. Ruxolitinib‐treated mice exhibited reduced inflammation, including decreased ear swelling and diminished pruritus. Furthermore, reductions in immune cell populations, including T cells and serum biomarker IL‐13, were observed in ruxolitinib‐treated mice. Transcriptome analysis revealed increased STAT3 expression and decreased skin barrier gene FLG in AD‐related cytokine‐treated RHS. Regardless of tape stripping, ruxolitinib‐treated skin explants exhibited decreased IL13RA1 expression and increased expression of skin barrier genes FLG, FLG2 and LOR. Ruxolitinib treatment in mice resulted in decreased inflammation and pruritus, along with increased expression of skin barrier proteins through downregulation of IL‐13. Consistently, ruxolitinib‐treated human skin explants demonstrated enhanced expression of skin barrier proteins, while IL‐13 treatment of RHS led to downregulation of these proteins. These findings support data from human clinical trials indicating reduced SCORAD, pruritus and inflammatory phenotypes in AD patients treated with ruxolitinib.


  • Open Access

    Malassezia and the Asian menopausal skin

    by Bala Davient, Jagpreet Kaur Rikhraj, Aarthi Ravikrishnan, Pritisha Rozario, Cheryl Leong, Ahmad Nazri Mohamed Naim, Nathania Chan, The HELIOS Study Team, John Common, John Campbell Chambers, et al.

    Background: Post-menopausal women undergo significant dermatological changes, including thinning skin and reduced sebaceous gland activity, alongside increased incidence of dermatological diseases and hair loss. These changes reshape the skin’s ecological niche, influencing the skin mycobiome composition and behavior. Malassezia , a lipid-dependent human pathobiont and dominant fungal resident of skin, has been implicated in several dermatological disorders. We hypothesize that shifts in Malassezia populations contribute to post-menopausal skin disorders through altered host–microbe interactions. Results: Shotgun metagenomics of facial and scalp skin from 345 Asian women were stratified by menopausal stage (pre- [N=171], peri- [N=36], and post-menopausal [N=138]) and revealed the presence of seven out of the seventeen recognized Malassezia species: M. globosa , M. restricta , M. arunalokei , M. furfur , M. dermatis , M. japonica , and M. sympodialis . Detection frequencies of several species varied markedly across menopausal groups. Notably, M. globosa was detected 20% more frequently on the scalp of post- versus pre-menopausal women. Reduced sebum concentration on post-menopausal women’s skin correlated with increased M. globosa abundance. In vitro co-culture of keratinocytes with Malassezia spp. showed cells tolerated fungal loads up to 10 4.5 CFU/cm², but severe cytotoxicity was observed at ≥10 5.5 CFU/cm². M. globosa elicited the highest cytotoxicity towards keratinocytes. All Malassezia spp. tested invaded keratinocytes and triggered strong pro-inflammatory responses. Notably, IL-1α, IL-1β, IL-6, IL-8, IL-21, TNF-α, GM-CSF, G-CSF, and MMP1 were significantly overproduced. Transcriptomics of keratinocytes exposed to toxic fungal loads revealed a gene expression profile characteristic of hyperproliferative and undifferentiated cells, alongside elevated expression of NLRP3 , a key inflammasome sensor involved in pyroptosis. Conclusions: Menopause is associated with distinct shifts in Malassezia spp. prevalence and abundance. Reduced skin lipids and thickness may increase fungal burden relative to host cells, promoting inflammation and barrier dysfunction. Malassezia ’s ability to invade keratinocytes suggests a mechanism for immune evasion and induction of chronic inflammation. Furthermore, keratinocytes exposed to high fungal loads exhibited a transcriptomic profile indicative of hyperproliferation and impaired differentiation, resembling patterns observed in psoriasis, seborrheic dermatitis, and other inflammatory skin conditions. Our co-culture model provides mechanistic insight into Malassezia -driven skin inflammation and offers a platform to develop targeted therapies for post-menopausal skin disorders.


  • Comment on ‘A proposal for a new pathogenesis-guided classification for inherited epidermal differentiation disorders’

    by Mark Eisner, Thomas Sharkey, John Common, Neil Rajan

    Here, we respond to the proposal for a gene-based nomenclature for epidermal differentiation disorders. We outline potential pitfalls around inequity and also opportunities this approach may offer.


  • Open Access

    Protocol to reconstruct an in vitro 3D full-thickness skin equivalent model with collagen I in 6- and 12-well inserts

    by Khek-Chian Tham, Seong Soo Lim, Carine Bonnard, John E.A. Common


  • Open Access

    Portimine A toxin causes skin inflammation through ZAKα-dependent NLRP1 inflammasome activation

    by Léana Gorse, Loïc Plessis, Stephen Wearne, Margaux Paradis, Miriam Pinilla, Rae Chua, Seong Soo Lim, Elena Pelluz, Gee-Ann Toh, Raoul Mazars, et al.

    In 2020–2021, a “mysterious illness” struck Senegalese fishermen, causing severe acute dermatitis in over one thousand individuals following exposure through drift-net fishing activity. Here, by performing deep analysis of the environmental samples we reveal the presence of the marine dinoflagellate Vulcanodinium rugosum and its associated cyclic imine toxins. Specifically, we show that the toxin PortimineA, strongly enriched in environmental samples, impedes ribosome function in human keratinocytes, which subsequently activates the stress kinases ZAKα and P38 and promotes the nucleation of the human NLRP1 inflammasome, leading to the release of IL-1β/IL-18 pro-inflammatory cytokines and cell death. Furthermore, cell-based models highlight that naturally occurring mutations in the P38-targeted sites of human NLRP1 are unable to respond to PortimineA exposure. Finally, the development and use of human organotypic skins and zebrafish models of PortimineA exposure demonstrate that the ZAKα-NLRP1 axis drives skin necrosis and inflammation. Our results exemplify the threats to human health caused by emerging environmental toxins and identify ZAKα and NRLP1 as important pharmacological targets to mitigate PortimineA toxicity.